*, Harsha Prasada L (2015) Sevelamer Hydrochloride for Tumor Lysis Syndrome-related Hyperphosphatemia. Indian Pediatrics, 52. pp. 613-615. ISSN 0019-6061

PDF 613.pdf - Published Version Restricted to Repository staff only Download (53kB) | Request a copy

Abstract

Background: Tumour lysis syndrome is associated with high levels of uric acid, phosphate and potassium along with low levels of calcium and abnormal renal function. Sevelamer, an oral phosphate-binder is used in the treatment of hyperphosphatemia in children and adults on hemodialysis. Case characteristics: Two children with T-cell acute lymphoblastic leukemia who presented with a high tumour load and developed tumour lysis syndrome. Observation: Both children received Rasburicase and Sevelamer hydrochloride. The serum phosphate reduced to normal levels within 24-48 hrs of initiation of sevelamer hydrochloride. Message: Sevelamer appears to be an effective treatment for hyperphosphatemia associated with tumour lysis syndrome.

Actions (login required)

View Item